Douglas Love, Annexon CEO (Annexon)

IPO bound? Ac­tu­al­ly, An­nex­on was al­ready prepped and primed to toss its S-1 to Wall Street as in­vestors ral­lied

The Wall Street IPO shuf­fle gen­er­al­ly calls for a lit­tle dis­tance be­tween the crossover ante and the Wall Street dou­ble, but with the win­dow on the street wide open and biotech siz­zling hot, who’s wait­ing?

The crew at An­nex­on didn’t leave any­one in sus­pense for long about their IPO plans. A day af­ter the Bay Area biotech with clin­i­cal plans to tar­get neu­rode­gen­er­a­tion qui­et­ly un­veiled a $100 mil­lion raise, they were back with an S-1 out­lin­ing a pitch to dou­ble that — or more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.